Category: Amgen

Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034: Visiongain

Visiongain Reports Ltd Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS…

Continue Reading Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034: Visiongain

Translational Regenerative Medicine market is estimated to

Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading…

Continue Reading Translational Regenerative Medicine market is estimated to

Achievements, accolades highlight past year at VUMC | VUMC Reporter

  Editor’s note — the following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2023.   Whole-genome sequencing agreement Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies,…

Continue Reading Achievements, accolades highlight past year at VUMC | VUMC Reporter

Readout Newsletter: Amgen, Novartis, Chewy, Bluebird

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hullo! Turns out Jay Bradner is moving from academia and Novartis to serve as Amgen’s new CSO. Also, the FDA has a new registry of trial sponsors and investigators…

Continue Reading Readout Newsletter: Amgen, Novartis, Chewy, Bluebird

Seven precision medicine companies worth keeping an eye on

Precision medicine is an approach to tailoring treatments based on people’s genetic makeup, lifestyles and environment. These targeted interventions can tackle diseases like cancer, neurological as well as metabolic diseases. The global market value of the precision medicine industry, encompassing many companies, crossed 70 billion last year, and is expected…

Continue Reading Seven precision medicine companies worth keeping an eye on

Amgen (AMGN) Announces FDA Grants Priority Review to Tarlatamab Application for Advanced Small Cell Lung Cancer

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company’s Biologics License Application (BLA) for tarlatamab. Tarlatamab is a potential first-in-class, investigational delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE®) therapy for the treatment of adult patients…

Continue Reading Amgen (AMGN) Announces FDA Grants Priority Review to Tarlatamab Application for Advanced Small Cell Lung Cancer

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON–(BUSINESS WIRE)– Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has initiated its international confirmatory Phase 3 RAMP 301 trial (GOG-3097; ENGOT-ov81/NCRI), evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the…

Continue Reading Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Fibroblast Growth Factor Receptor 2 Inhibitor Market Focuses on Market Share, Size and Projected Forecast Till 2030 | by Isomjohnson | Dec, 2023

What is Fibroblast Growth Factor Receptor 2 Inhibitor? Fibroblast Growth Factor Receptor 2 (FGFR2) inhibitors have emerged as a promising therapeutic class in the field of precision medicine, particularly in the treatment of certain types of cancer. These inhibitors selectively target the FGFR2 signaling pathway, which is responsible for stimulating…

Continue Reading Fibroblast Growth Factor Receptor 2 Inhibitor Market Focuses on Market Share, Size and Projected Forecast Till 2030 | by Isomjohnson | Dec, 2023

Red Biotechnology Market Size, Share, Growth Report and Forecast 2024-2032

PRESS RELEASE Published December 11, 2023   According to the report by Expert Market Research (EMR), the global red biotechnology market is projected to grow at a CAGR of 6.20% between 2024 and 2032. Aided by the escalating demand for therapeutic solutions, innovative drugs, and genetic engineering, the market is expected to…

Continue Reading Red Biotechnology Market Size, Share, Growth Report and Forecast 2024-2032

Latest Research Report on Biotechnology Market Share and Industrial Overview till 2031

PRESS RELEASE Published December 11, 2023 The assessment of the “Biotechnology Market” in 2023 constitutes a comprehensive and meticulous study, encompassing a wide array of factors that impact business growth opportunities, challenges, potential risks, and emerging trends across diverse global regions. This extensive report presents precise and up-to-date information on…

Continue Reading Latest Research Report on Biotechnology Market Share and Industrial Overview till 2031

Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

“It’s hoped that [longer persistence with oral DEC-C] would translate to better outcomes because those patients are able to stay on a treatment that takes time to work,” said Amer Zeidan, MD, in a presentation during the meeting. Retrospective, real-world results showed that oral decitabine and cedazuridine (DEC-C) and standard…

Continue Reading Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

Analyses Probe into Co-Mutation Activity of Sotorasib in KRAS-Mutant NSCLC

Devika Das, MD Associate Professor UAB Medicine Birmingham, AL LINK TO PART 1 Targeted Oncology: What data support the use of sotorasib (Lumakras) in patients with non–small cell lung cancer (NSCLC) and a KRAS G12C mutation? DEVIKA DAS, MD: The CodeBreaK 100 study [NCT03600883] was a registrational phase 2 study….

Continue Reading Analyses Probe into Co-Mutation Activity of Sotorasib in KRAS-Mutant NSCLC

Gene Therapy Market estimated to grow according to forecasts

Allied Market Research has published a study report Gene Therapy Market Size is Anticipated to Garner USD 46.5 billion by 2030, registering a CAGR of 22.8% Allied Market Research published a report, titled, “Gene Therapy Marketby Vector Type (Viral Vector, Non-Viral Vector), by Therapy (In Vivo Therapy, Ex Vivo Therapy), by…

Continue Reading Gene Therapy Market estimated to grow according to forecasts

Blau syndrome Market Scope and overview

Blau syndrome Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The report provides an overview including definitions, applications, product launches, developments, challenges, and regions. It is predicted that the market will show strong development due to the driven consumption in various…

Continue Reading Blau syndrome Market Scope and overview

Metagenomics Industry Forecasting a Noteworthy Surge to US$ 394.2 Million by 2033-FMI Report

The metagenomics industry is expected to grow at a compound annual growth rate (CAGR) of 6.9% between 2023 and 2033, according to latest market analysis by FMI. The market forecast for 2023 is $202.9 million USD. By 2033, the estimated value is expected to reach US$ 394.2 million. The market…

Continue Reading Metagenomics Industry Forecasting a Noteworthy Surge to US$ 394.2 Million by 2033-FMI Report

Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023

PRESS RELEASE Published December 4, 2023 DelveInsight’s, “Psoriasis Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product…

Continue Reading Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023

How the UK is setting new standards for genomic research and better health care

Last week, UK Biobank released the sequence analysis of half a million samples to approved researchers across academia, industry, charitable organizations, and government. Experts believe this milestone will greatly aid scientists in drug discovery and other biomedical developments. “This is a fundamentally important project in terms of enabling access to…

Continue Reading How the UK is setting new standards for genomic research and better health care

UK Biobank Revolutionizes Global Medical Research with World’s Largest Genome Sequencing Dataset

Credit: UK Biobank Advertisement In a groundbreaking development, UK Biobank has released a vast dataset from whole genome sequencing of half a million participants, a move poised to revolutionize medical research and treatment development. This unparalleled dataset available to approved researchers globally, excludes personal identifiers, ensuring participant privacy. This achievement…

Continue Reading UK Biobank Revolutionizes Global Medical Research with World’s Largest Genome Sequencing Dataset

Syngene Bioinformatics Research Job – Biotech Apply Online

“Breaking News: Syngene Hiring Research Investigator For Cutting-Edge Biotech Role!” –Must See– Syngene Bioinformatics Research Job – Biotech Can Also Apply Online Incorporated in 1993, Syngene International Ltd. is an innovation-focused global discovery, development, and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods,…

Continue Reading Syngene Bioinformatics Research Job – Biotech Apply Online

UK Biobank unveils world’s largest genetic data set

In a momentous landmark for medical research, UK Biobank has today [Thursday 30 November] unveiled incredible new data from whole genome sequencing of its half a million participants. This is set to drive the discovery of new diagnostics, treatments and cures and, uniquely, is available to approved researchers worldwide, via a protected…

Continue Reading UK Biobank unveils world’s largest genetic data set

Britain’s genetic databank to unveil largest-ever sequencing release

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The pioneering UK Biobank is to publish the largest-ever release of genetic sequencing data to boost the research and development of drugs to treat diseases ranging from heart conditions to…

Continue Reading Britain’s genetic databank to unveil largest-ever sequencing release

UK Biobank Releases Whole Genome Data from Half a Million People

After five years, more than 350,000 hours of genome sequencing, and over £200 million of investment, UK Biobank is releasing the world’s largest-by-far single set of human sequencing data—completing the most ambitious project of its kind ever undertaken. The new data, whole genome sequences of its half a million participants,…

Continue Reading UK Biobank Releases Whole Genome Data from Half a Million People

UK Biobank reveals new data from world’s largest genetic project

UK Biobank has shared new data from its world’s largest whole genome sequencing project with researchers worldwide for the discovery of new diagnostics, treatments and cures. The set of sequencing data is the biggest ever seen globally and was curated across five years, with more than 350,000 hours of genome…

Continue Reading UK Biobank reveals new data from world’s largest genetic project

Phase 3 Trials Reveal New Standards of Care for NSCLC

Data from several recent phase 3 trials support changes to standard care for non-small cell lung cancer (NSCLC), according to researchers. Results from the MARIPOSA trial suggest that amivantamab plus lazertinib represents a new first-line standard of care for patients with advanced, EGFR-mutant NSCLC.1 The MARIPOSA-2 trial suggests that amivantamab…

Continue Reading Phase 3 Trials Reveal New Standards of Care for NSCLC

Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals

For Immediate Release Chicago, IL – November 24, 2023 – Today, Zacks Equity Research discusses Gilead Sciences, Inc. GILD, CRISPR Therapeutics AG CRSP, ACADIA Pharmaceuticals Inc. ACAD, Dynavax DVAX and Ligand Pharmaceuticals Inc. LGND. Industry: Biotech Link: www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright It has been a choppy ride for the biotech industry in 2023…

Continue Reading Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals

Latest biotech news: fundraises, deals, clinical trials

Here is Labiotech’s weekly roundup of the latest biotech news. Whether it is partnerships, clinical trials, or fundraising, we have got you covered. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Viva Biotech closes $210 million funding round  Chinese company Viva Biotech closed…

Continue Reading Latest biotech news: fundraises, deals, clinical trials

A Deep Dive into Trends, Players, and Growth

The gene therapy market has evolved into a juggernaut in the healthcare sector, displaying an extraordinary trajectory of growth. As of 2023, the gene therapy market has surged to a remarkable value of USD 6.36 billion, and the projection for the forthcoming years is nothing short of astonishing. Forecasts indicate…

Continue Reading A Deep Dive into Trends, Players, and Growth

7 Protein Folding Updates From 2023

For over 50 years, scientists were stuck on the protein-folding problem. It’s like trying to figure out how a complex origami structure folds up. But then, in 2020, DeepMind’s AlphaFold cracked the code. It aced a big contest by predicting how proteins fold with an amazing 90% accuracy. Jump ahead…

Continue Reading 7 Protein Folding Updates From 2023

The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…

Continue Reading The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

Is CRISPR Therapeutics the Best Gene-Editing Stock?

A striking analogy can be drawn between the development of monoclonal antibodies and the emergence of CRISPR-based gene editing. Both technologies took roughly 10 years to transition from the laboratory to the market, and both have transformed the field of human medicine. Since the first Food and Drug Administration (FDA)…

Continue Reading Is CRISPR Therapeutics the Best Gene-Editing Stock?

Amgen hiring Grad Intern – NGS Bioinformatics in United States

HOW MIGHT YOU DEFY IMAGINATION?Do more with the knowledge you’re working hard to acquire and the passion you already have. At Amgen, our shared mission—to serve patients—drives all that we do. It is key to our becoming one of the world’s leading biotechnology companies, reaching over 10 million patients worldwide….

Continue Reading Amgen hiring Grad Intern – NGS Bioinformatics in United States

Grad Intern – NGS Bioinformatics job with Amgen

HOW MIGHT YOU DEFY IMAGINATION? Do more with the knowledge youre working hard to acquire and the passion you already have. At Amgen, our shared missionto serve patientsdrives all that we do. It is key to our becoming one of the worlds leading biotechnology companies, reaching over 10 million patients…

Continue Reading Grad Intern – NGS Bioinformatics job with Amgen

Gene Therapy Market Size Worth US$ 16.8 Billion, Globally, by 2032 – Exclusive Report by IMARC Group

The global gene therapy market size reached US$ 5.1 Billion in 2023. By 2032, it will reach a value of US$ 16.8 Billion, growing at a CAGR of 13.9% (2024-2032). SHERIDAN, WYOMING, USA, November 16, 2023 /EINPresswire.com/ — How Big is the Gene Therapy Market? The global gene therapy market…

Continue Reading Gene Therapy Market Size Worth US$ 16.8 Billion, Globally, by 2032 – Exclusive Report by IMARC Group

Capricor Therapeutics hits enrollment target for pivotal DMD study, eyes expansion of CAP-1002 By Investing.com

© Reuters. Capricor Therapeutics (NASDAQ:) has achieved its enrollment goal for the HOPE-3 Phase 3 pivotal study, investigating a treatment for Duchenne Muscular Dystrophy (DMD), according to the details shared in their recent earnings call. The company also unveiled plans to accelerate the approval process for its lead asset, CAP-1002,…

Continue Reading Capricor Therapeutics hits enrollment target for pivotal DMD study, eyes expansion of CAP-1002 By Investing.com

deCODE Genetics Finds 4% of Icelanders Carry an Actionable Genotype

Scientists at deCODE genetics, a subsidiary of Amgen, have been focusing on actionable genotypes detected in the Icelandic population. Recently, the researchers found that approximately 1 in 25 Icelanders carried an actionable genotype and that carrying such a genotype was associated with a reduced life span. This research is published…

Continue Reading deCODE Genetics Finds 4% of Icelanders Carry an Actionable Genotype

Exploring the Impact of Actionable Genotypes on Lifespan

Scientists at deCODE genetics, a subsidiary of Amgen, have conducted groundbreaking research on actionable genotypes in the Icelandic population. The study, published in The New England Journal of Medicine, reveals that carrying an actionable genotype is linked to a reduced lifespan, a fact that has significant implications for precision medicine…

Continue Reading Exploring the Impact of Actionable Genotypes on Lifespan

Landmark academic-industry partnership harvests human genome “fruits” for research – Nashville Medical News

  By Bill Snyder   The first fruits of a landmark academic-industry partnership that is harvesting the depth and breadth of the human genome to better understand and treat disease will become available to researchers in the spring of 2024. Underway is whole genome sequencing of DNA samples from approximately…

Continue Reading Landmark academic-industry partnership harvests human genome “fruits” for research – Nashville Medical News

Landmark academic-industry partnership harvests human genome “fruits” for research | VUMC Reporter

  by Bill Snyder The first fruits of a landmark academic-industry partnership that is harvesting the depth and breadth of the human genome to better understand and treat disease will become available to researchers in the spring of 2024. Underway is whole genome sequencing of DNA samples from approximately 35,000…

Continue Reading Landmark academic-industry partnership harvests human genome “fruits” for research | VUMC Reporter

10 Asia-Pacific companies leading innovation in the region

Asia-Pacific is now establishing itself as a global innovation hub, with China, Japan, and Korea leading the space in overall innovative pipeline assets in the region. The life sciences industry is thriving, and there has been a shift in the region from predominantly producing generics to developing innovative technologies, with…

Continue Reading 10 Asia-Pacific companies leading innovation in the region

Sustained Reductions in Lp(a) Achieved With Novel siRNA Drug

In an early phase multicenter clinical study, large reductions in lipoprotein(a), or Lp(a), were achieved with a well-tolerated small interfering RNA (siRNA) therapeutic, lepodisiran. The reductions in serum Lp(a) in patients receiving lepodisiran were dose dependent but adverse events were not, said Steven E. Nissen, MD, professor of medicine at…

Continue Reading Sustained Reductions in Lp(a) Achieved With Novel siRNA Drug

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

A single injection cut Lp(a) by 94% at 48 weeks and was well tolerated, findings that researchers say justify further studies. Lepodisiran, a long-duration, short-interfering RNA (siRNA), dramatically slashed Lp(a) levels in a small, phase I study presented this weekend at the American Heart Association (AHA) 2023 Scientific Sessions. Lead…

Continue Reading Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Astria Therapeutics shares Q3 results, positive phase 1a data, and pipeline expansion By Investing.com

© Reuters. Astria Therapeutics recently reported its third-quarter financial results and provided a corporate update, highlighting its promising Phase 1a data for STAR-0215, a potential preventative treatment for Hereditary Angioedema (HAE). The company also announced the expansion of its pipeline with STAR-0310, a potential therapy for atopic dermatitis. Key takeaways…

Continue Reading Astria Therapeutics shares Q3 results, positive phase 1a data, and pipeline expansion By Investing.com

More Thoughts on Artificial Intelligence

I published Thoughts on Artificial Intelligence on 19 July 2023. Since then, developments in AI have continued at a breath-taking speed. In here, I want to share new thoughts on AI that I have, as well as provide updates on some of the initial discussions. Let’s start with the new thoughts, in…

Continue Reading More Thoughts on Artificial Intelligence

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria…

Continue Reading Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Abstract Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study…

Continue Reading Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Metagenomics Market Anticipates a Surge, Projected to Reach US$ 394.2 Million by 2033 Amidst the Rise in Chronic Illness

According to recent market research by FMI, the metagenomics market is anticipated to register a CAGR of 6.9% between 2023 and 2033. In 2023, the market estimate would be US$ 202.9 million. The value is predicted to reach US$ 394.2 million by 2033. The market is mainly driven by surging investments from…

Continue Reading Metagenomics Market Anticipates a Surge, Projected to Reach US$ 394.2 Million by 2033 Amidst the Rise in Chronic Illness

CAR T Cell Therapy Market Demands, Industry Analysis and Forecast 2032 | Taiwan News

Report Ocean has recently published a revised figures report on the worldwide CAR T Cell Therapy market. Growth prospects and difficulties are noted in the paper. A tool for evaluating the potential for new goods and services is the constraints and opportunity analysis. This aids businesses in locating and forecasting…

Continue Reading CAR T Cell Therapy Market Demands, Industry Analysis and Forecast 2032 | Taiwan News

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

Key Points Question  Is clonal hematopoiesis of indeterminate potential (CHIP) detected at the time of hematopoietic stem transplant (HCT) associated with increased rates of cardiovascular disease (CVD) among patients with multiple myeloma (MM) following HCT? Finding  In this cohort study of patients with MM undergoing HCT, CHIP was highly prevalent…

Continue Reading Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

Study provides insights into the epidemiology and genetics of clonal hematopoiesis

A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and somatic and germline genetics of clonal hematopoiesis. Whole genome sequence data from Iceland and the UK Biobank, combined with a unique somatic mutation Barcoding strategy, was used to…

Continue Reading Study provides insights into the epidemiology and genetics of clonal hematopoiesis

CytomX Therapeutics Reports Third Quarter 2023 Financial

– CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 – – CX-2051 (EpCAM-directed ADC) comprehensive preclinical profile presented at 14th Annual World ADC Conference; IND filing on track for year-end – – Updated CX-801 (conditionally activated interferon alpha-2b) preclinical data presented at…

Continue Reading CytomX Therapeutics Reports Third Quarter 2023 Financial

Amgen confirms FDA accepted Biologics License Application for ABP 938

(Image Credit: AdobeStock/Aha-Soft) In their Q3 Earnings call, Amgen confirmed The United States Food and Drug Administration (FDA) accepted the Biologics License Application for ABP 938.1 ABP 938 is an investigational biosimilar to EYLEA (aflibercept), which is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein, while a BLA…

Continue Reading Amgen confirms FDA accepted Biologics License Application for ABP 938

Biotechnology Poised For Disruptive And Explosive Growth|Gilead Sciences Inc., Regeneron Pharmaceuticals Inc.

HTF Market Intelligence published a new research document of 150+pages on “Biotechnology Market Insights, to 2028″ with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Biotechnology market was mainly…

Continue Reading Biotechnology Poised For Disruptive And Explosive Growth|Gilead Sciences Inc., Regeneron Pharmaceuticals Inc.

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now

Biotech stocks are amid a multiyear slump. While it would be easy to lay the blame squarely on the Federal Reserve’s dramatic rate hikes, that’s not the whole story. Far from it. In reality, many biotechs brought this situation upon themselves. During the previous bull market, scores of preclinical and…

Continue Reading 2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now

Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

Oral and Poster Abstracts 652. Multiple Myeloma: Clinical and Epidemiological: Poster III Research, adult, Translational Research, assays, Plasma Cell Disorders, bioinformatics, Diseases, Lymphoid Malignancies, computational biology, Technology and Procedures, Study Population, Human, molecular testing, omics technologies Dor D. Abelman1,2, Jenna Eagles1*, Stephanie Pedersen1*,…

Continue Reading Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma

How French pharma giant Sanofi is betting big on AI

The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. According to a recent report, the number of AI companies involved in drug discovery and development increased from 62 in 2011 to 400 in 2022. This AI-driven transformation is catching…

Continue Reading How French pharma giant Sanofi is betting big on AI

Elucidating the effects of microbubble pinch-off dynamics on mammalian cell viability

doi: 10.1002/bit.28582. Online ahead of print. Affiliations Expand Affiliations 1 Department of Mechanical Engineering, Boston University, Boston, Massachusetts, USA. 2 Department of Mechanical Engineering, Dunwoody College of Technology, Minneapolis, Minnesota, USA. 3 Amgen, Cambridge, Massachusetts, USA. 4 Global Processing Engineering, Biogen, Cambridge, Massachusetts, USA. Item in Clipboard Oliver McRae et al….

Continue Reading Elucidating the effects of microbubble pinch-off dynamics on mammalian cell viability

A Deep Dive into the Latest Market Trends, Market Segmentation, and Competitive Ana

Fibroblast Growth Factor Receptor 2 Inhibitor Market Analysis and Latest Trends Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitors are drugs that work by inhibiting the activity of the FGFR2 receptor, which plays a crucial role in cell growth, differentiation, and embryonic development. These inhibitors are primarily used in the treatment…

Continue Reading A Deep Dive into the Latest Market Trends, Market Segmentation, and Competitive Ana

Beyond Semaglutide, a Coming Pipeline of New Antiobesity Meds

With nutrient-stimulated hormone therapies for obesity in phase 3 trials, and activin-receptor inhibitors the next upcoming drug class, highly effective treatments for obesity are on the horizon. “We are at a watershed [moment] brought on by the recent introduction of highly effective antiobesity medications,” said Ania M. Jastreboff, MD, PhD,…

Continue Reading Beyond Semaglutide, a Coming Pipeline of New Antiobesity Meds

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

CytomX Therapeutics Inc. – IND filing for CX-801 anticipated by the end of 2023 – SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that preclinical data supporting CX-801, its conditionally activated…

Continue Reading CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

PacBio Announces Third Quarter 2023 Financial Results

MENLO PARK, Calif., Oct. 30, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023. Third quarter results Revenue of $55.7 million, a 72% increase compared with $32.3 million in the prior-year period. Instrument revenue of $34.7 million compared with $11.4 million in the prior-year…

Continue Reading PacBio Announces Third Quarter 2023 Financial Results

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

On Sept. 14, 1990, Ken Griffey Jr. and Ken Griffey Sr. made history by hitting back-to-back home runs. However, the day is also memorable for another remarkable event: A 4-year-old girl named Ashanti DeSilva became the first person to receive gene therapy, a procedure that involved injecting her with modified…

Continue Reading Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

City of Hope part of successful international

image:  “This is the first Phase 3 clinical trial to show a benefit over standard of care in patients with the KRAS G12C mutation whose cancer progressed after receiving standard chemotherapy. The efficacy results from our study are promising in this population with unmet needs and should set a new…

Continue Reading City of Hope part of successful international

City of Hope Joins Global Trial: Sotorasib Proves Successful for Metastatic Colorectal Cancer

LOS ANGELES — An international Phase 3 clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab. City of Hope,…

Continue Reading City of Hope Joins Global Trial: Sotorasib Proves Successful for Metastatic Colorectal Cancer

Study identifies promising treatment for advanced colorectal cancer

An international Phase 3 clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab. City of Hope was a participating…

Continue Reading Study identifies promising treatment for advanced colorectal cancer

major antitrust cases in recent years

Antitrust laws are put in place to prevent unlawful activities like price fixing, as well as monopolies from forming, typically tied to big pharma. If these powerful companies were to swallow smaller biotechs in an attempt to fix prices, it would stifle competition, result in limited options for consumers, thereby…

Continue Reading major antitrust cases in recent years

Phase 3 data confirm rapid efficacy of nemolizumab for atopic dermatitis treatment

October 26, 2023 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading Phase 3 data confirm rapid efficacy of nemolizumab for atopic dermatitis treatment

The Age of Aquarius – RNA, the Epicenter of Genetic Information

The veil on genetic information was lifted by the advent of gene cloning and sequencing technologies in the 1970s. The discovery and purification of bacterial nucleases capable of cutting DNA at specific sequences and ligases capable of joining them enabled DNA from any species – or mRNAs converted to complementary…

Continue Reading The Age of Aquarius – RNA, the Epicenter of Genetic Information

Abbvie Set to Announce Q3 2023 Results Amid Robust Immunology Drug Sales By Investing.com

AbbVie (NYSE:) is poised to announce its Q3 2023 results on Thursday, October 27, following a previous quarter that saw an earnings surprise of 4.30%. This announcement comes as the company’s immunology drugs, Skyrizi and Rinvoq, continue to show robust sales performance. Notably, Skyrizi has proven superior over competitors Otezla…

Continue Reading Abbvie Set to Announce Q3 2023 Results Amid Robust Immunology Drug Sales By Investing.com

Phase 3 innovaTV 301 Trial Shows Potential of Tisotumab Vedotin in Cervical Cancer

Ignace B. Vergote, MD, PhD In the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628), tisotumab vedotin-tftv (Tivdak) demonstrated a 30% reduction in the risk of death compared with investigator’s choice of chemotherapy when utilized in the second- or third-line for patients with recurrent or metastatic cervical cancer with disease progression on…

Continue Reading Phase 3 innovaTV 301 Trial Shows Potential of Tisotumab Vedotin in Cervical Cancer

Amgen Announces Data From The Global Phase 3 Codebreak 300 Trial Evaluating Two Doses Of Lumakrasin In Combination With Vectibix -October 22, 2023 at 10:31 am EDT

Oct 22 (Reuters) – Amgen Inc: * AMGEN SAYS CODEBREAK 300 TRIAL WAS STUDIED IN PATIENTS WITH CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER * AMGEN ANNOUNCES DATA FROM THE GLOBAL PHASE 3 CODEBREAK 300 TRIAL EVALUATING TWO DOSES OF LUMAKRASIN IN COMBINATION WITH VECTIBIX * AMGEN SAYS DATA SHOWS STATISTICALLY…

Continue Reading Amgen Announces Data From The Global Phase 3 Codebreak 300 Trial Evaluating Two Doses Of Lumakrasin In Combination With Vectibix -October 22, 2023 at 10:31 am EDT

RNA Targeting Small Molecule Drug Discovery Market Size, Share And Growth Analysis For 2023-2032

(MENAFN– EIN Presswire) RNA Targeting Small Molecule Drug Discovery Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032 The Business Research Company’s RNA Targeting Small Molecule Drug Discovery Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032 The Business Research Company’s global market reports…

Continue Reading RNA Targeting Small Molecule Drug Discovery Market Size, Share And Growth Analysis For 2023-2032

ERS Genomics Limited (‘ERS’) completes licensing agreement with Syngene International

ERS Genomics Limited (‘ERS’) completes licensing agreement with Syngene International, India’s leading Contract Research, Development and Manufacturing Organization Syngene gains access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners.  DUBLIN, Oct. 18, 2023 /PRNewswire/ — ERS Genomics, co-founded by…

Continue Reading ERS Genomics Limited (‘ERS’) completes licensing agreement with Syngene International

CytomX Therapeutics Presents Preclinical Profile of

– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload – – Preclinical data demonstrate a favorable predicted therapeutic index and efficacy across multiple EpCAM-expressing tumors, including colorectal cancer (CRC) – – CX-2051 IND filing expected by year-end 2023…

Continue Reading CytomX Therapeutics Presents Preclinical Profile of

Grad Intern – NGS Bioinformatics – Positive Work Culture at Amgen-Workday in Washington DC

We are hiring a resilient Grad Intern – NGS Bioinformatics to join our high calibre team at Amgen-Workday in Washington DC.Growing your career as a Internship Grad Intern – NGS Bioinformatics is an incredible opportunity to develop relevant skills.If you are strong in negotiation, problem-solving and have the right initiative…

Continue Reading Grad Intern – NGS Bioinformatics – Positive Work Culture at Amgen-Workday in Washington DC

six companies leading the way

Singapore set out to become a global biotech hub back in 2000, and, although still awaiting its big success story in the industry, it is currently a leading hub in the APAC region for R&D, biopharma manufacturing, and commercial operations, with a growing startup ecosystem that includes numerous biotech companies….

Continue Reading six companies leading the way

Grad Intern – NGS Bioinformatics Jobs at Amgen in Washington

HOW MIGHT YOU DEFY IMAGINATION? Do more with the knowledge you’re working hard to acquire and the passion you already have. At Amgen, our shared mission—to serve patients—drives all that we do. It is key to our becoming one of the world’s leading biotechnology companies, reaching over 10 million patients…

Continue Reading Grad Intern – NGS Bioinformatics Jobs at Amgen in Washington

Protein Engineering Market Size is Expanding at USD 15.25

Ottawa, Oct. 11, 2023 (GLOBE NEWSWIRE) — The global protein engineering market size is projected to hit around USD 15.25 billion by 2032. Advancements in protein engineering technology, including new gene editing tools like CRISPR-Cas9 and the development of novel computational algorithms, have opened new opportunities for protein design and…

Continue Reading Protein Engineering Market Size is Expanding at USD 15.25

Protein Engineering Market Size is Expanding at USD 15.25 Billion by 2032

Ottawa, Oct. 11, 2023 (GLOBE NEWSWIRE) — The global protein engineering market size is projected to hit around USD 15.25 billion by 2032. Advancements in protein engineering technology, including new gene editing tools like CRISPR-Cas9 and the development of novel computational algorithms, have opened new opportunities for protein design and…

Continue Reading Protein Engineering Market Size is Expanding at USD 15.25 Billion by 2032

ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

A 2020 Nature Cancer study found that patients with advanced non-small cell lung cancer (NSCLC) who had undetectable circulating tumor (ct)DNA after chemoradiotherapy “had excellent outcomes whether or not they received consolidation immune checkpoint inhibition (CICI) … the ctDNA response pattern early during CICI identified patients responding to consolidation therapy.”…

Continue Reading ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Key Points Question  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically…

Continue Reading Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Cell And Gene Therapy Market Outlook and Opportunities in Grooming Regions 2030

Cell And Gene Therapy Market Size Projections : The global cell and gene therapy market is estimated to be valued at US$ 22.7 billion in 2023 and is expected to exhibit a CAGR of 28.7% during the forecast period (2023-2030). Global Cell And Gene Therapy Market 2023 research report represents a detailed overview of the current market situation and…

Continue Reading Cell And Gene Therapy Market Outlook and Opportunities in Grooming Regions 2030

Analysts Weigh in on Healthcare Giants Amgen and Intellia Therapeutics

According to analysts, Evan Seigerman of BMO Capital has maintained a Hold rating on Amgen (AMGN) with a price target of $260.00. Seigerman, a 4-star analyst, has an average return of 5.3% and a 44.2% success rate. Seigerman focuses on stocks in the Healthcare sector, including Structure Therapeutics, Vertex Pharmaceuticals,…

Continue Reading Analysts Weigh in on Healthcare Giants Amgen and Intellia Therapeutics

BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

In patients treated in the first-line setting (n=20), the confirmed objective response rate (ORR) was 65%, with a 100% disease control rate (DCR) (95% CI: 83.2, 100). In assessable patients in the second-line setting (n=13), the ORR was 54%, with a DCR of 85% (95% CI: 54.6, 98.1). Among patients…

Continue Reading BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

In patients treated in the first-line setting (n=20), the confirmed objective response rate (ORR) was 65%, with a 100% disease control rate (DCR) (95% CI: 83.2, 100). In assessable patients in the second-line setting (n=13), the ORR was 54%, with a DCR of 85% (95% CI: 54.6, 98.1). Among patients…

Continue Reading BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

Chronic Idiopathic Urticaria Pipeline, Clinical Trials, Emerging Drugs and FDA Approvals 2023 (Updated)

PRESS RELEASE Published September 30, 2023 DelveInsight’s, “Chronic Idiopathic Urticaria Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Idiopathic Urticaria Pipeline landscape. It covers the Chronic Idiopathic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the…

Continue Reading Chronic Idiopathic Urticaria Pipeline, Clinical Trials, Emerging Drugs and FDA Approvals 2023 (Updated)

Chronic Urticaria Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)

PRESS RELEASE Published September 30, 2023 DelveInsight’s, “Chronic Urticaria Pipeline Insight 2023” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline…

Continue Reading Chronic Urticaria Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)

Tezepelumab reduces mucus plugs in adults with uncontrolled asthma

Tezepelumab is associated with a reduction in occlusive mucus plugs versus placebo in adults with uncontrolled asthma, according to a study published in the October issue of NEJM Evidence. Lars H. Nordenmark, Ph.D., from AstraZeneca in Oslo, Norway, and colleagues assessed the anti-inflammatory effect of tezepelumab in participants of the…

Continue Reading Tezepelumab reduces mucus plugs in adults with uncontrolled asthma

Gene Therapy in Oncology Market Demand, Growth by 2023-2030

PRESS RELEASE Published September 25, 2023 “Gene Therapy in Oncology Market 2023” Report is Made by Executing a Superb Research Process to Gather Key Information of this Global Gene Therapy in Oncology Market. The Analysis is Dependent on Just Two Segments, Especially, Chief Research and Extensive Secondary Research. The Gene…

Continue Reading Gene Therapy in Oncology Market Demand, Growth by 2023-2030

The data in our DNA | Opinion

In the two decades since the Human Genome Project was declared finished (if not complete), DNA sequencing technology has advanced to the point where reading whole genomes is becoming routine. In 2003 the cost of sequencing an individual’s complete genome was in the order of millions of dollars, today it’s…

Continue Reading The data in our DNA | Opinion

Pegozafermin improves fibrosis in patients with NASH, could advance to phase 3 development

September 22, 2023 2 min read Source/Disclosures Published by: Disclosures: Loomba reports financial relationships with 89bio, Aardvark Therapeutics, Allergan, Altimmune, Amgen Inc., Anylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CohBar, Eli Lilly, Galectin, Galmed Pharmaceuticals, Genfit, Gilead Sciences, Glympse bio, Hanmi Pharmaceutical, Hightide, Inipharm, Intercept Pharmaceuticals, Inventica, Ionis Pharmaceuticals, Janssen…

Continue Reading Pegozafermin improves fibrosis in patients with NASH, could advance to phase 3 development

AAD Reading Room | After Latest Findings, FDA Approval for Lebrikizumab Could Happen This Fall

Most patients with moderate-to-severe atopic dermatitis (AD) who received lebrikizumab (Adbry) every 2 weeks maintained a favorable response to the drug out to the 1-year mark, recent trial data showed. Perhaps just as importantly, people receiving the drug every 4 weeks maintained a substantial response, suggesting less-frequent treatments are required…

Continue Reading AAD Reading Room | After Latest Findings, FDA Approval for Lebrikizumab Could Happen This Fall

Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) (“Travere”) today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) versus irbesartan. FILSPARI demonstrated long-term kidney function preservation and achieved a clinically…

Continue Reading Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI

Diffuse Large B-cell Lymphoma Market to Show Immense Growth

New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) — Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out – AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda The DLBCL market has a diverse pipeline, with the emergence of…

Continue Reading Diffuse Large B-cell Lymphoma Market to Show Immense Growth

RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials

RayzeBio and Neumora Therapeutics have joined the public markets, and in contrast to the plethora of preclinical biotech IPOs of 2020 and 2021, these two Wall Street newcomers each have multiple drug candidates in the clinic. That clinical trial progress, including lead programs in Phase 3 testing, enticed investors, enabling…

Continue Reading RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials

mRNA Manufacturing and Synthesis Services Market Report Latest Trends and Future Opportunities Analysis

PRESS RELEASE Published September 13, 2023 InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on “Global mRNA Manufacturing and Synthesis Services Market– By. Type of Industry (Therapeutics/Vaccine Developers, CDMO Organizations, Custom Synthesis/Other Service Providers) By Scale of Operation (Research / Preclinical, Clinical, Commercial) and By Application…

Continue Reading mRNA Manufacturing and Synthesis Services Market Report Latest Trends and Future Opportunities Analysis

Fibroblast Growth Factor Receptor 2 market research report has seen immense growth at an exponential CAGR rate of 7% from 2023 to 2030 and provides in-depth analysis of Fibroblast Growth Factor Receptor 2 market.

The “Fibroblast Growth Factor Receptor 2 Market” is focused on controlling cost, and improving efficiency. Moreover, the reports offer both the demand and supply aspects of the market. The Fibroblast Growth Factor Receptor 2 market is expected to grow annually by 7% (CAGR 2023 – 2030). Fibroblast Growth Factor Receptor…

Continue Reading Fibroblast Growth Factor Receptor 2 market research report has seen immense growth at an exponential CAGR rate of 7% from 2023 to 2030 and provides in-depth analysis of Fibroblast Growth Factor Receptor 2 market.

Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on Results From CodeBreaK 101 Trial

Amgen has initiated a phase 3 study of sotorasib (Lumakras) plus carboplatin and pemetrexed in the first-line treatment of KRASG12C-mutant advanced non–small cell lung cancer (NSCLC) due to results from the CodeBreaK 101 clinical trial (NCT04185883). The results of the study were included as an oral presentation at the International…

Continue Reading Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on Results From CodeBreaK 101 Trial

Jensen Uses ChatGPT to Dissolve Plastic

ChatGPT is a household name now. If you ask anyone how they use the chatbot, the most common response you would get is to draft emails, code, write resumes, and improve the quality of some basic tasks. For example, Satya Nadella uses ChatGPT to understand poetry. Sam Altman uses it…

Continue Reading Jensen Uses ChatGPT to Dissolve Plastic

The Top 25 Healthcare Technology Leaders of Houston for 2023

The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Houston for 2023. Houston stands out as a prominent hub for medical device manufacturing, pharmaceuticals, and health research, boasting a thriving ecosystem encompassing over 1,100 well-established life sciences and biotechnology companies. These visionary-led enterprises are…

Continue Reading The Top 25 Healthcare Technology Leaders of Houston for 2023

GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification

Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK Vasiliki Lagou, Anuj Goel, Hugh Watkins & Mark I. McCarthy Human Genetics, Wellcome Sanger Institute, Hinxton, UK Vasiliki Lagou VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium Vasiliki Lagou Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia Longda Jiang…

Continue Reading GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification